NO20002590L - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine

Info

Publication number
NO20002590L
NO20002590L NO20002590A NO20002590A NO20002590L NO 20002590 L NO20002590 L NO 20002590L NO 20002590 A NO20002590 A NO 20002590A NO 20002590 A NO20002590 A NO 20002590A NO 20002590 L NO20002590 L NO 20002590L
Authority
NO
Norway
Prior art keywords
paroxetine
solid
formulations
solutions
dissolved
Prior art date
Application number
NO20002590A
Other languages
Norwegian (no)
Other versions
NO20002590D0 (en
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20002590D0 publication Critical patent/NO20002590D0/en
Publication of NO20002590L publication Critical patent/NO20002590L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives farmasøytiske formuleringer av paroxetin, hvor paroxetinet er i løsning i en fast, halvfast eller flytende bærer. Løsningene benyttes til fylling av kapsler, eller selvbærende faste løsninger formes til faste doseringsformer som tabletter eller pellets. Det beskrives også nye flytende formuleringer, hvor et solubiliseringsmiddel benyttes til å solubilisere paroxetin i oljer og/eller lipider, samt fremgangsmåter for å unngå at andre paroxetinformer omdannes til hemihydratet, ved bruk av vannfrie eller hydrofobe bærere eller hjelpestoffer.Pharmaceutical formulations of paroxetine are disclosed, wherein the paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or self-supporting solid solutions are formed into solid dosage forms such as tablets or pellets. Also described are new liquid formulations, wherein a solubilizing agent is used to solubilize paroxetine in oils and / or lipids, and methods for preventing other paroxetine informants from being converted to the hemihydrate, using anhydrous or hydrophobic carriers or excipients.

NO20002590A 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine NO20002590L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (2)

Publication Number Publication Date
NO20002590D0 NO20002590D0 (en) 2000-05-19
NO20002590L true NO20002590L (en) 2000-07-19

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002590A NO20002590L (en) 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine

Country Status (24)

Country Link
EP (1) EP1033986A1 (en)
JP (1) JP2001523718A (en)
KR (1) KR20010032320A (en)
CN (1) CN1279608A (en)
AP (1) AP2000001821A0 (en)
AR (1) AR015485A1 (en)
AU (1) AU1168099A (en)
BG (1) BG104527A (en)
BR (1) BR9814220A (en)
CO (1) CO4970832A1 (en)
DZ (1) DZ2658A1 (en)
EA (1) EA200000552A1 (en)
GB (1) GB9724544D0 (en)
HU (1) HUP0100580A3 (en)
IL (1) IL136106A0 (en)
MA (1) MA24704A1 (en)
NO (1) NO20002590L (en)
OA (1) OA11385A (en)
PE (1) PE20000381A1 (en)
PL (1) PL340555A1 (en)
SK (1) SK7342000A3 (en)
TR (1) TR200001423T2 (en)
WO (1) WO1999026625A1 (en)
ZA (1) ZA9810637B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
ATE311883T1 (en) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd STABLE PHARMACEUTICAL USE FORM FOR PAROXETINE ANHYDRATE
CA2341984A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives
DE19930454A1 (en) * 1999-07-02 2001-01-04 Knoll Ag Solid paroxetine-containing preparations
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ATE374602T1 (en) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc ORAL CAPSULE FORMULATION WITH IMPROVED PHYSICAL STABILITY
SE0200475D0 (en) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral pharmaceutical preparation
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
JP2001508460A (en) * 1997-01-15 2001-06-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Paroxetine composition

Also Published As

Publication number Publication date
CO4970832A1 (en) 2000-11-07
GB9724544D0 (en) 1998-01-21
HUP0100580A2 (en) 2002-04-29
BG104527A (en) 2001-04-30
JP2001523718A (en) 2001-11-27
WO1999026625A1 (en) 1999-06-03
KR20010032320A (en) 2001-04-16
ZA9810637B (en) 2000-05-22
AU1168099A (en) 1999-06-15
DZ2658A1 (en) 2003-03-22
IL136106A0 (en) 2001-05-20
CN1279608A (en) 2001-01-10
MA24704A1 (en) 1999-07-01
SK7342000A3 (en) 2000-12-11
EP1033986A1 (en) 2000-09-13
BR9814220A (en) 2001-12-26
NO20002590D0 (en) 2000-05-19
PE20000381A1 (en) 2000-05-07
OA11385A (en) 2004-01-27
TR200001423T2 (en) 2000-10-23
PL340555A1 (en) 2001-02-12
EA200000552A1 (en) 2000-10-30
AR015485A1 (en) 2001-05-02
HUP0100580A3 (en) 2002-05-28
AP2000001821A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
ES2191862T3 (en) LIQUID COMPOSITION INCLUDING AN HIV PROTEASE INHIBITOR AND A FATTY ACID OF C12-C18.
DE69927963D1 (en) GELABLE PHARMACEUTICAL COMPOSITIONS
NO20002133L (en) Solid state solutions and dispersions of weakly water-soluble drugs
DE69006365D1 (en) UNCOATED PHARMACEUTICAL REACTION TABLET.
KR920700036A (en) Active Type Vitamin D₃Solid Agents with Improved Stability
ES2110377T1 (en) GALLENIC FORMULATION OF PHENOFIBRATE AND APPLICATION OF THE SAME.
ES2196621T3 (en) ADMINISTRATION SYSTEMS OF PHARMACOS THAT USE LIQUID GLASS STRUCTURES.
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
ES2042541T3 (en) A PROCEDURE FOR PREPARING A DELAYED PHARMACEUTICAL FORMULATION CONTAINING XANTHANE GUM.
ATE215370T1 (en) SELF-EMULSIFYING FORMULATION CONTAINING LIPOPHILIC COMPOUNDS
DE69940674D1 (en) ORAL ADMINISTRATION OF ADENOSINE ANALOG
DE58902457D1 (en) RETARDED MEDICAL FORM AND METHOD FOR THE PRODUCTION THEREOF.
DK1173153T3 (en) Oral pharmaceutical preparations containing long chain triglycerides and lipophilic surfactants
ES8502333A1 (en) Long-acting matrix tablet formulations.
KR850000239A (en) Preparation and Encapsulation Method of Particles
KR850001693A (en) Method for preparing amosulolol hydrochloride long-acting formulation
NO950134L (en) Formulations for orally administered pharmaceutical agents
BG104527A (en) Formulations comprising dissolved paroxetine
BR0013106A (en) Floating pharmaceutical composition, tablet, and tablet preparation process.
ES8402504A1 (en) PROCEDURE FOR PREPARING SOFT ALCALOID GELATIN CAPSULES FROM CORNEZUELO DE CENTENO.
NO931697L (en) LHRH ANTAGONISTS
FR2799660B1 (en) SUPERCRITICAL FLUID EXTRACTION PROCESS
ATE300293T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POORLY SOLUBLE MEDICINAL SUBSTANCES
Wiseman et al. The distribution, excretion and metabolism of benzquinamide
ES2064619T3 (en) TETRAHYDROPYRANILIC DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL OR VETERINARY COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application